Kexing Biopharm’s TL1A/LIGHT Bispecific Antibody Affords at 2026 BFC-Cytiva World Healthcare Summer season BD & Funding Convention

San Diego, California–(Newsfile Corp. – June 29, 2026) – Lately, the Head of World Commercial Building at Kexing Biopharm Co., Ltd. (hereinafter veritably known as “Kexing Biopharm”, 688136.SH) used to be invited to lend a hand the 2026 BFC-Cytiva World Healthcare Summer season BD & Funding Convention. She delivered a roadshow speech showcasing the Company’s revolutionary pipeline in autoimmune ailments, oncology, and ophthalmology to the world pharmaceutical and investment communities, highlighting the most long-established R&D growth of GB24, a TL1A/LIGHT bispecific antibody for inflammatory bowel illness (IBD).

The BFC-Cytiva World Healthcare Summer season BD & Funding Convention is with out doubt one of many sector’s most influential world industry collaboration and investment events within the biopharmaceutical sector. Held in San Diego, USA, on June 21, 2026, this year’s conference attracted commerce leaders, along with MNC senior executives, world institutional investors, and revolutionary biotech firms.

The conference featured excessive-stage dialogues on core subject matters akin to world innovation, injurious-border collaboration, and rising therapeutic modalities. As a representative Chinese pharmaceutical firm growing globally, Kexing Biopharm delivered a roadshow speech focusing on its self-developed core pipelines for most cancers cachexia, autoimmune and inflammatory ailments and ophthalmology. GB24 is a first-in-class (FIC) bispecific antibody candidate focusing on both TL1A and LIGHT, designed in step with the helpful and mechanistic synergy and complementarity of these two targets. TL1A is a core driver of intestinal inflammation in IBD sufferers, while LIGHT performs a severe role in chronic fibrosis. Via synergistic dual-pathway regulation, GB24 achieves a dual “anti-inflammatory + anti-fibrotic” mechanism of action, which is anticipated to interrupt throughout the efficacy ceiling of present single-aim IBD therapies.

Inflammatory bowel illness (IBD), along with Crohn’s illness and ulcerative colitis, is seeing a real rise in world occurrence. GB24’s differentiated advantages consist of: first, its aim need permits it to have a “grasp swap” space, enabling regulation of inflammatory cascades at the source; 2d, the addition of anti-fibrotic potential permits it to take care of intestinal fibrosis in mid-to-plain stage sufferers, reaching comprehensive illness management for IBD from early to straightforward phases. As a groundbreaking subsequent-generation product within the Company’s IBD portfolio, preclinical analysis for GB24 is advancing abruptly and has yielded a chain of certain data. Preclinical animal mannequin data has confirmed that GB24 is highly effective in inhibiting ulcers and fibrosis, vastly making improvements to intestinal characteristic and microstructure, and propelling IBD remedy into a new section of comprehensive illness management.

After all, Kexing Biopharm will adhere to its “Innovation + Internationalization” technique, focusing on patient wants and always advancing R&D and innovation to make contributions to safeguarding world health.

Contact:

Kexing Biopharm

Zheng Haiyan

[email protected]

https://www.kexingbiopharm.com/

To peek the source version of this press beginning, please negate over with https://www.newsfilecorp.com/beginning/303267